Bristol-Myers Squibb Company (BMY)
Bristol-Myers Squibb: A Better Earnings Outlook, Stronger Momentum Heading Into 2025
Bristol-Myers Squibb delivered a significant earnings beat in Q2, driving shares up 20% since spring and boosting sector performance. Despite concerns about long-term EPS, strong Q2 results and improved guidance support a buy rating, with a valuation target near $76. BMY's technical chart shows bullish signals, including a potential golden cross and improved RSI momentum, indicating a favorable trend.
Bristol-Myers Squibb Company (BMY) Wells Fargo 2024 Healthcare Conference (Transcript)
Bristol-Myers Squibb Company (NYSE:BMY ) Wells Fargo 2024 Healthcare Conference September 6, 2024 12:00 AM ET Company Participants Adam Lenkowsky - Chief Commercialization Officer Conference Call Participants Mohit Bansal - Wells Fargo Cerena Chen - Wells Fargo Mohit Bansal All right. Good morning on a Friday.
Bristol-Myers Still A Value Play Despite Appreciating 26.56% From 2024 Lows
BMY has appreciated 26.56% since July but remains undervalued with a 4.8% yield, trading at less than 8 times 2025 earnings. Q2 earnings validated my thesis with a $680 million revenue beat and a $6.47 swing in non-GAAP EPS, showing strong profitability. Rate cuts will allow BMY to refinance nearly $50 billion in debt, reducing interest expenses and boosting margins.
Bristol-Myers Squibb-backed Zenas BioPharma seeks up to $689.7 mln valuation in US IPO
Zenas BioPharma, which is developing immunology-based therapies, said on Friday it is targeting a valuation of as much as $689.7 million in its initial public offering in the United States.
Bristol Myers Squibb (BMY) Falls More Steeply Than Broader Market: What Investors Need to Know
Bristol Myers Squibb (BMY) closed at $49.80 in the latest trading session, marking a -0.32% move from the prior day.
Bristol-Myers Squibb Company (BMY) Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript)
Bristol-Myers Squibb Company (NYSE:BMY ) Morgan Stanley 22nd Annual Global Healthcare Conference September 5, 2024 1:05 PM ET Company Participants Chris Boerner - Chief Executive Officer David Elkins - Executive Vice President and Chief Financial Officer Conference Call Participants Terence Flynn - Morgan Stanley Terence Flynn Okay, great. Thanks for joining us everybody.
2 Reasons Bristol Myers Squibb Stock Could Be a Bargain, Down 34% From Its All-Time High
Recent results from Bristol Myers Squibb support an improving outlook. The company is benefiting from strong demand for its new medications.
2 No-Brainer Large-Cap Stocks to Buy With $500 Right Now
An investment in these two stocks could pay off handsomely over the next five to 10 years. Bristol Myers is an established healthcare business with a portfolio of blockbuster drugs.
Bristol Myers Squibb (BMY) Advances But Underperforms Market: Key Facts
Bristol Myers Squibb (BMY) closed at $49.95 in the latest trading session, marking a +0.46% move from the prior day.
Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know
Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
The Magnificent 7 Dividend Stocks Every Passive Income Investor Should Own
24/7 Wall St. Insights Dividend stocks are starting to outperform in the second half of 2024.
Here's Why a Handful of Pharmaceutical Stocks Rose Wednesday
Shares of several drugmakers and biotechnology firms moved higher on Wednesday, notching some of the day's top performances in the S&P 500.
